A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or olderJean‐Luc Harousseau, Joseph Brandwein, Dominique Bordessoule et al.|Blood|2009Cited by 146
Dasatinib in imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia in blast phase after 2 years of follow‐up in a phase 3 studyGiuseppe Saglio, Hervé Dombret, Andreas Hochhaus et al.|Cancer|2010Cited by 125